What is the mechanism of action for Rystiggo?
Rystiggo (rozanolixizumab-noli) is a neonatal Fc receptor blocker. It’s a monoclonal antibody that may be used to treat an autoimmune disorder called generalized myasthenia gravis.
Rystiggo works by targeting a protein called neonatal Fc receptor (FcRn). By blocking FcRn, Rystiggo prevents autoantibodies from attaching to it instead. When autoantibodies attach to FcRn, they are recycled into the body instead of getting broken down. Too many autoantibodies can worsen MS symptoms by interfering with signaling between nerves and muscles. Rystiggo ensures harmful autoantibodies are broken down normally in cells.
References
Rystiggo [package insert]. (Revised June 2023). UCB, Inc. Accessed 06/14/2024 at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3c0eb8c2-c042-4954-b451-3baa77f5e6d1
www.rystiggo.com. How Rystiggo works. Accessed 06/14/2024.
Zhu, L., et. al. (2023). FcRn inhibitors: a novel option for the treatment of myasthenia gravis. In: Neural Regeneration Research. Accessed 06/14/2024 at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154512/
Related medical questions
- How long does it take Rystiggo to work?
- Can I stop taking Mestinon (pyridostigmine)?
- How does Mestinon help with myasthenia gravis?
- What's the mechanism of action for Mestinon (pyridostigmine)?
- Is Mestinon an Immunosuppressant?
- How long does it take for Ultomiris to work?
- How does Empaveli compare to Soliris?
Drug information
- Rystiggo Information for Consumers
- Rystiggo prescribing info & package insert (for Health Professionals)
- Side Effects of Rystiggo (detailed)
Related support groups
- Rystiggo (2 questions, 3 members)
- Myasthenia Gravis (14 questions, 96 members)